85 related articles for article (PubMed ID: 20445512)
1. Anti-TNF treatment in Crohn's disease: toward tailored therapy?
D'Haens G
Am J Gastroenterol; 2010 May; 105(5):1140-1. PubMed ID: 20445512
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
[TBL] [Abstract][Full Text] [Related]
3. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
4. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
5. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
6. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
7. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
9. Treatment of vulval Crohn's disease with infliximab.
Preston PW; Hudson N; Lewis FM
Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
[TBL] [Abstract][Full Text] [Related]
10. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.
Danese S; Fiorino G; Reinisch W
Aliment Pharmacol Ther; 2011 Jul; 34(1):1-10. PubMed ID: 21539588
[TBL] [Abstract][Full Text] [Related]
11. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
14. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
15. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
16. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
17. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
18. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P;
Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865
[TBL] [Abstract][Full Text] [Related]
19. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
